Difference between revisions of "Drug index"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "back to top" to "back to top")
Line 5: Line 5:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Abemaciclib (LY2835219)]] '''in clinical trials'''
 
*[[Abemaciclib (LY2835219)]] '''in clinical trials'''
Line 68: Line 68:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Bacillus Calmette-Guerin (BCG)]]
 
*[[Bacillus Calmette-Guerin (BCG)]]
Line 96: Line 96:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Cabazitaxel (Jevtana)]]
 
*[[Cabazitaxel (Jevtana)]]
Line 145: Line 145:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Dabigatran (Pradaxa)]]
 
*[[Dabigatran (Pradaxa)]]
Line 190: Line 190:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Eculizumab (Soliris)]]
 
*[[Eculizumab (Soliris)]]
Line 216: Line 216:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Factor VIIa, recombinant (NovoSeven RT)]]
 
*[[Factor VIIa, recombinant (NovoSeven RT)]]
Line 250: Line 250:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Galeterone (TOK-001)]] '''in clinical trials'''
 
*[[Galeterone (TOK-001)]] '''in clinical trials'''
Line 269: Line 269:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Haloperidol (Haldol)]]
 
*[[Haloperidol (Haldol)]]
Line 282: Line 282:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Ibandronate (Boniva)]]
 
*[[Ibandronate (Boniva)]]
Line 317: Line 317:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Lactulose]]
 
*[[Lactulose]]
Line 346: Line 346:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Mannitol]]
 
*[[Mannitol]]
Line 379: Line 379:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Nabilone (Cesamet)]]
 
*[[Nabilone (Cesamet)]]
Line 397: Line 397:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Obinutuzumab (Gazyva)]]
 
*[[Obinutuzumab (Gazyva)]]
Line 423: Line 423:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Paclitaxel (Taxol)]]
 
*[[Paclitaxel (Taxol)]]
Line 477: Line 477:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Rabeprazole (Aciphex)]]
 
*[[Rabeprazole (Aciphex)]]
Line 507: Line 507:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Samarium-153 (Quadramet)]]
 
*[[Samarium-153 (Quadramet)]]
Line 532: Line 532:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Tacrolimus (Prograf)]]
 
*[[Tacrolimus (Prograf)]]
Line 579: Line 579:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Valacyclovir (Valtrex)]]
 
*[[Valacyclovir (Valtrex)]]
Line 604: Line 604:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Warfarin (Coumadin)]]
 
*[[Warfarin (Coumadin)]]
Line 624: Line 624:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[:Category:Alkylating agents|Alkylating agents]]
 
*[[:Category:Alkylating agents|Alkylating agents]]
Line 642: Line 642:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
<div style="column-count:2;-moz-column-count:2;-webkit-column-count:2">
 
<div style="column-count:2;-moz-column-count:2;-webkit-column-count:2">
Line 678: Line 678:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[:Category:Antiandrogens|Antiandrogens]]
 
*[[:Category:Antiandrogens|Antiandrogens]]
Line 698: Line 698:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[:Category:Antibody medications|Antibody medications]]
 
*[[:Category:Antibody medications|Antibody medications]]
Line 711: Line 711:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[:Category:Antibacterials|Antibacterials]]
 
*[[:Category:Antibacterials|Antibacterials]]
Line 732: Line 732:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[:Category:Anticoagulants|Anticoagulants]]
 
*[[:Category:Anticoagulants|Anticoagulants]]
Line 753: Line 753:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[:Category:Erythrocyte growth factors|Erythrocyte growth factors]]
 
*[[:Category:Erythrocyte growth factors|Erythrocyte growth factors]]
Line 762: Line 762:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[:Category:REMS_program|Drugs in a REMS program]]
 
*[[:Category:REMS_program|Drugs in a REMS program]]
Line 773: Line 773:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
Line 848: Line 848:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[:Category:Intraarterial chemotherapy|Intraarterial (IA) chemotherapy]]
 
*[[:Category:Intraarterial chemotherapy|Intraarterial (IA) chemotherapy]]
Line 862: Line 862:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
Line 934: Line 934:
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
−
|[[#toc|back to top]]
+
|[[#top|back to top]]
 
|}
 
|}
 
*[[Antidepressants and other psychiatric medications in cancer care]]
 
*[[Antidepressants and other psychiatric medications in cancer care]]

Revision as of 03:38, 24 October 2016

Alphabetically

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

J

K

L

back to top

M

back to top

N

back to top

O

back to top

P

back to top

Q

R

back to top

S

back to top

T

back to top

U

V

back to top

W

back to top

X

Z

By Category

Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).

Drugs in a REMS program

Cytotoxic Chemotherapy

back to top

Kinase inhibitors

back to top

Endocrine therapy

back to top

Investigational and Discontinued

Biologics

back to top

Supportive Medications

back to top

Radioactive agents

Benign Hematology Medications

back to top

Hematopoietic Growth Factors

back to top

Miscellaneous

back to top

Medications by Condition

back to top

Medications by Route of Administration

back to top

Medications by Year of Approval

back to top

Interesting and Helpful Links

back to top

References

  1. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.
  2. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  3. ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Drug_index&oldid=12096"